Psychiatric Medications and Pregnancy: What You Need to Know Before Stopping

Research consistently shows that 70–80% of pregnant people on psychiatric medications discontinue them after learning they are pregnant — and that the large majority do so without consulting their prescriber. The reasons are understandable: a desire to protect the fetus, a belief that “natural” is safer, concern about teratogenicity from internet searches, and the cultural messaging that pregnancy and psychiatric medication are fundamentally incompatible.

The clinical reality is more complicated. Abrupt discontinuation of psychiatric medications during pregnancy creates multiple risks:

• Discontinuation syndrome from abrupt stopping (SSRI, SNRI, benzodiazepine) — independent of pregnancy risk
• Rapid relapse of the underlying condition, often within weeks in high-risk diagnoses like bipolar disorder
• Untreated psychiatric illness exposing the fetus to the documented biological consequences of maternal mental illness
• The person carrying the pregnancy is in the most acute period of vulnerability for psychiatric relapse across the lifespan — the postpartum period — and stopping medication now sets up a much worse postpartum situation

Untreated depression and anxiety during pregnancy are not benign. The physiological stress response — specifically elevated cortisol and corticotropin-releasing hormone (CRH) — has documented effects on fetal development:

• Preterm birth risk is elevated in untreated maternal depression and anxiety — CRH plays a direct role in labor initiation, and elevated maternal CRH is associated with earlier labor
• Low birth weight — chronic cortisol elevation reduces fetal growth through multiple mechanisms including uteroplacental blood flow restriction
• Postpartum depression amplification — untreated depression during pregnancy is one of the strongest predictors of postpartum depression severity. The postpartum period is the highest-risk window for psychiatric relapse in women's lives; entering it without adequate treatment is clinically dangerous
• Neurodevelopmental effects — emerging evidence links prolonged prenatal exposure to maternal stress to altered HPA axis calibration in the infant, with downstream effects on stress reactivity and neurodevelopment

The frame that needs to change: the question is not “is it safe to take medication during pregnancy?” It is “what is the risk of this medication versus the risk of this untreated illness in this specific person?” The second question is much harder — it requires clinical judgment, individualized risk assessment, and honest conversation with both a psychiatrist and an OB.

SSRIs are the most commonly prescribed psychiatric medications during pregnancy, and they also have the most robust safety data. The most important points:

• Sertraline and escitalopram have the most pregnancy safety data and are generally considered the first-line choices when SSRI treatment is continued in pregnancy. Major malformation studies — including large registry-based studies with tens of thousands of exposures — show no significant increase in major congenital malformations above baseline for these two agents.
• Persistent Neonatal Adaptation Syndrome (PNAS) — approximately 30% of neonates exposed to SSRIs in late pregnancy develop PNAS: jitteriness, irritability, feeding difficulties, and mild respiratory distress in the first days of life. This is temporary, resolves spontaneously within 1–2 weeks, and does not require treatment in most cases. It is the most common SSRI-related neonatal issue and is manageable with appropriate neonatal monitoring.
• Persistent Pulmonary Hypertension of the Newborn (PPHN) — there is a relative risk increase of approximately 1.5–2x for PPHN with late-pregnancy SSRI exposure. The absolute risk remains very low: approximately 1.2 cases per 1,000 births, compared to a baseline of approximately 1–2 per 1,000. This risk is worth discussing with your OB and factoring into delivery planning — it does not, on its own, mandate stopping SSRIs in a person who needs them.

Lithium has historically been considered highly teratogenic due to early case reports linking it to Ebstein's anomaly — a rare cardiac malformation. More recent, larger meta-analyses have substantially revised that picture:

• The absolute risk of Ebstein's anomaly with first-trimester lithium exposure is approximately 0.1–0.6% — elevated compared to the population baseline (~0.005%) but dramatically lower than early case series suggested
• The 2017 NEJM meta-analysis revised downward the Ebstein risk significantly; it remains a consideration but not an absolute contraindication
• Lithium discontinuation risk is severe — approximately 50% of people with bipolar disorder relapse within weeks of stopping lithium. For someone with Bipolar I, this may mean a manic episode during pregnancy that requires hospitalization, carries its own fetal risk, and is far harder to treat safely in pregnancy than the underlying medication
• Close OB monitoring protocol when lithium is continued includes fetal echocardiogram at 16–18 weeks, serum level monitoring (lithium levels drop in pregnancy due to increased renal clearance and require upward dose adjustment), and delivery planning

Lamotrigine (Lamictal) is generally considered among the safer antiepileptic drugs (AEDs) and mood stabilizers for use in pregnancy — particularly compared to valproate, which has a well-established teratogenic profile and is contraindicated in pregnancy when alternatives are available.

The primary clinical challenge with lamotrigine in pregnancy is pharmacokinetic: lamotrigine levels drop significantly during pregnancy — often by 50% or more — because rising estrogen levels induce CYP450 enzymes that accelerate lamotrigine metabolism. This means a person who is therapeutically stable on lamotrigine before pregnancy may relapse during the second or third trimester not because the drug is failing but because the effective dose has been cut in half.

Close serum level monitoring throughout pregnancy with proactive dose adjustment is the standard of care. After delivery, estrogen levels drop rapidly and lamotrigine metabolism normalizes — dose typically needs to be reduced back to pre-pregnancy levels within the first few weeks postpartum to avoid toxicity.

Benzodiazepines are not the first choice for anxiety management during pregnancy — but they are not an absolute contraindication, and the decision to taper vs. continue requires clinical judgment.

• Neonatal sedation and withdrawal are the primary neonatal concerns with benzodiazepine exposure, particularly in late pregnancy. Neonates may experience hypotonia, respiratory depression, and withdrawal symptoms. These are typically manageable with neonatal monitoring and supportive care.
• Abrupt discontinuation risk — for a person on a daily benzodiazepine for significant anxiety or panic disorder, abrupt cessation carries its own risk: severe anxiety rebound, seizure risk (at higher doses), and discontinuation symptoms that are themselves physiologically stressful to the pregnancy. A supervised taper is always preferable to abrupt stopping.
• The older teratogenicity data linking benzodiazepines to cleft palate has not been consistently replicated in larger, better-controlled studies. The absolute malformation risk is considered low.

Atypical antipsychotics are used in pregnancy for bipolar disorder, schizophrenia, and augmentation of depression. The primary concerns:

• Gestational diabetes risk — atypicals with significant metabolic effects (olanzapine, clozapine, quetiapine) are associated with increased gestational diabetes risk. Metabolic monitoring — glucose, HbA1c, weight gain tracking — is required throughout pregnancy.
• Neonatal adaptation — similar to SSRIs, late-pregnancy antipsychotic exposure can produce neonatal adaptation symptoms including abnormal movements, irritability, and feeding difficulties that typically resolve within the first weeks.
• The general clinical consensus: for a person with bipolar disorder, schizophrenia, or treatment-resistant depression where antipsychotic medication is providing necessary stabilization, the benefit of continued treatment outweighs the risks in most cases. Discontinuing an antipsychotic during pregnancy — particularly in someone with psychosis or severe BD — carries far greater risk than the medication.

The postpartum period — specifically the first 6–12 weeks after delivery — is the highest-risk period for psychiatric relapse in women's lives. This is true across diagnoses: the precipitous drop in estrogen and progesterone postpartum destabilizes mood regulation, sleep deprivation compounds psychiatric vulnerability, and the stress demands of newborn care reduce every psychological buffer.

A treatment plan that covers pregnancy but stops at delivery is clinically incomplete. The psychiatric medication and monitoring plan must include:

• Postpartum medication protocol established before delivery — what the plan is for the first 24–48 hours, the first weeks, and the first months
• Breastfeeding considerations — for most medications, the amount transmitted in breast milk is low and the clinical benefit of breastfeeding (for both parent and infant) typically outweighs exposure risk; this is a conversation with the prescriber and the pediatrician, not a unilateral stop
• Psychiatric follow-up scheduled before delivery, not weeks postpartum — the highest-risk period should not be navigated without a scheduled check-in
• A specific plan for what to watch for (and who to call) if mood destabilizes in the postpartum period

The ideal model is coordinated care: the psychiatrist or PMHNP and the OB communicating directly, sharing notes, and making medication decisions collaboratively. In practice, this coordination is inconsistent — and the psychiatric prescriber often has to be an active advocate for their patient within the OB system.

If you are pregnant and on psychiatric medication, the most important things to do:

• Do not change your medication without involving your prescriber — a brief call before stopping is infinitely better than stopping and calling when you've relapsed
• Tell your OB what psychiatric medications you are taking, even if it feels irrelevant to the pregnancy — they need this information for delivery planning and neonatal care coordination
• Ask your prescriber to communicate with your OB — not all OBs will initiate this, but most psychiatric prescribers will if asked
• If you are in a high-risk pregnancy or have a serious psychiatric diagnosis (bipolar I, schizophrenia, recurrent MDD), ask for a maternal-fetal medicine (MFM) consultation — MFM specialists have more experience with complex medication- pregnancy decisions than general OB practice